AdAlta secures key manufacturing agreements for AD-214
Filed with ASX · · 3 pages · English
In the deck
Earlier from AdAlta
- Appendix 4C - Quarter Ended 31 March 2018
- AdAlta to advance improved lung fibrosis therapy, AD-214
- AdAlta collaborator awarded NHMRC grant
- AdAlta granted key Australian Patent
- Commercial agreement with XL-protein
Later from AdAlta
- Completion of Capital Raise - $4.25m to advance AD-214
- Appendix 4C - Quarter ended 30 June 2018
- Investor presentation and conference call
- Change of Registry Address: Automic P/L - Sydney Office
- Manufacturing Update
Follow AdAlta into a list and get an email when it puts out news.
Follow AdAlta